| PTLE 0.282 51.53% | SOXS 3.65 11.56% | MSPR 0.664 27.57% | SCNX 0.8182 15.35% | NVDA 198.69 -3.96% | SQQQ 13.79 6.16% | ORIS 0.1603 -0.12% | BYND 1.33 -4.32% | PFE 24.3 -1.46% | HTZ 6.73 36.23% | PLTR 190.74 -7.94% | TSLL 20.34 -10.16% | ETHA 24.28 -10.37% | ASST 1.25 -1.57% | IBIT 57.18 -5.53% | GRAB 5.785 -4.70% | INTC 37.03 -6.25% | PLUG 2.52 -8.36% | ONDS 5.96 -3.09% | OPEN 6.92 -8.83% | CHR 0.136 8.11% | FGL 0.5165 26.94% | DNN 2.74 -6.00% | TSLA 444.26 -5.15% | WTO 0.0497 -6.23% | CAPT 0.6615 31.77% | NFE 1.35 14.41% | SOXL 42.8 -11.90% | BITF 3.84 -6.57% | ETHD 5.26 20.92% | T 24.44 -0.37% | EPWK 0.0748 3.60% | F 12.79 -1.69% | SPY 675.24 -1.19% | SOFI 29.37 -4.11% | KVUE 15.97 -1.05% | ACHR 9.56 -8.25% | CIFR 22.51 -1.10% | QQQ 619.25 -2.03% | HIMS 42.79 -3.60% | GPUS 0.3494 -7.03% | TQQQ 111.08 -6.12% | LQD 110.68 0.14% | BTBT 3.18 -7.02% | AAL 12.65 -5.17% | TZA 8.21 5.26% | BURU 0.29 -7.91% | NCLH 18.79 -15.28% | RGTI 35.18 -10.07% | BTG 4 -5.77%

SANUWAVE Health, Inc. (OTC:SNWV) Demonstrates Superior Capital Efficiency

SANUWAVE Health, Inc. (OTC:SNWV) is a company that focuses on developing and commercializing non-invasive, high-energy, acoustic pressure shockwave technology for regenerative medicine and other applications. The company aims to provide innovative solutions for wound care, orthopedics, and other medical fields. In a competitive landscape, SANUWAVE stands out due to its efficient capital management.

In the analysis of SANUWAVE's financial performance, the company exhibits a Return on Invested Capital (ROIC) of 54.33%, significantly higher than its Weighted Average Cost of Capital (WACC) of 15.34%. This results in a ROIC to WACC ratio of 3.54, indicating that SANUWAVE is highly efficient in generating returns over its cost of capital. This efficiency is a key factor in assessing the company's potential for growth and profitability.

When compared to its peers, SANUWAVE's performance is impressive. Rafarma Pharmaceuticals, Inc. (RAFA) has a ROIC of 3.03% and a WACC of 5.71%, resulting in a ROIC to WACC ratio of 0.53. This suggests that Rafarma is less efficient in generating returns over its cost of capital compared to SANUWAVE. Similarly, Pressure BioSciences, Inc. (PBIO) has a ROIC of 42.55% and a WACC of 67.83%, leading to a ROIC to WACC ratio of 0.63, further highlighting SANUWAVE's superior capital efficiency.

GulfSlope Energy, Inc. (GSPE) presents a stark contrast with a negative ROIC of -1932.28% and a WACC of 5.71%, resulting in a ROIC to WACC ratio of -338.50. This indicates significant inefficiency in generating returns over its cost of capital. In comparison, TSS, Inc. (TSSI) and Aspen Group, Inc. (ASPU) also fall short, with ROIC to WACC ratios of 2.05 and -0.25, respectively. SANUWAVE's ability to generate returns efficiently makes it a standout in this peer group.

Overall, SANUWAVE Health, Inc.'s strong ROIC to WACC ratio of 3.54 positions it as a leader in capital efficiency among its peers. This metric suggests that the company is effectively utilizing its invested capital to generate returns, making it a potentially attractive investment opportunity for those seeking companies with strong financial performance.

Published on: August 14, 2025